|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 22425 |
FusionGeneSummary for MRC2_VEZF1 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: MRC2_VEZF1 | Fusion gene ID: 22425 | Hgene | Tgene | Gene symbol | MRC2 | VEZF1 | Gene ID | 9902 | 7716 |
| Gene name | mannose receptor C type 2 | vascular endothelial zinc finger 1 | |
| Synonyms | CD280|CLEC13E|ENDO180|UPARAP | DB1|ZNF161 | |
| Cytomap | 17q23.2 | 17q22 | |
| Type of gene | protein-coding | protein-coding | |
| Description | C-type mannose receptor 2C-type lectin domain family 13 member EUPAR-associated proteinendocytic receptor (macrophage mannose receptor family)endocytic receptor 180macrophage mannose receptor 2urokinase-type plasminogen activator receptor-associated | vascular endothelial zinc finger 1putative transcription factor DB1zinc finger protein 161 | |
| Modification date | 20180523 | 20180519 | |
| UniProtAcc | Q9UBG0 | Q14119 | |
| Ensembl transtripts involved in fusion gene | ENST00000303375, ENST00000446119, ENST00000580916, | ENST00000584396, ENST00000581208, | |
| Fusion gene scores | * DoF score | 9 X 7 X 5=315 | 3 X 3 X 3=27 |
| # samples | 10 | 3 | |
| ** MAII score | log2(10/315*10)=-1.65535182861255 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(3/27*10)=0.15200309344505 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: MRC2 [Title/Abstract] AND VEZF1 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | MRC2 | GO:0030574 | collagen catabolic process | 12972549 |
| Tgene | VEZF1 | GO:0045944 | positive regulation of transcription by RNA polymerase II | 11504723 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | LD | PAAD | TCGA-3A-A9IH-01A | MRC2 | chr17 | 60705281 | + | VEZF1 | chr17 | 56060754 | - |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| Frame-shift | ENST00000303375 | ENST00000584396 | MRC2 | chr17 | 60705281 | + | VEZF1 | chr17 | 56060754 | - |
| Frame-shift | ENST00000303375 | ENST00000581208 | MRC2 | chr17 | 60705281 | + | VEZF1 | chr17 | 56060754 | - |
| intron-3CDS | ENST00000446119 | ENST00000584396 | MRC2 | chr17 | 60705281 | + | VEZF1 | chr17 | 56060754 | - |
| intron-3CDS | ENST00000446119 | ENST00000581208 | MRC2 | chr17 | 60705281 | + | VEZF1 | chr17 | 56060754 | - |
| intron-3CDS | ENST00000580916 | ENST00000584396 | MRC2 | chr17 | 60705281 | + | VEZF1 | chr17 | 56060754 | - |
| intron-3CDS | ENST00000580916 | ENST00000581208 | MRC2 | chr17 | 60705281 | + | VEZF1 | chr17 | 56060754 | - |
Top |
FusionProtFeatures for MRC2_VEZF1 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| MRC2 | VEZF1 |
| May play a role as endocytotic lectin receptordisplaying calcium-dependent lectin activity. Internalizesglycosylated ligands from the extracellular space for release inan endosomal compartment via clathrin-mediated endocytosis. May beinvolved in plasminogen activation system controlling theextracellular level of PLAUR/PLAU, and thus may regulate proteaseactivity at the cell surface. May contribute to cellular uptake,remodeling and degradation of extracellular collagen matrices. Mayplay a role during cancer progression as well as in other chronictissue destructive diseases acting on collagen turnover. Mayparticipate in remodeling of extracellular matrix cooperating withthe matrix metalloproteinases (MMPs).{ECO:0000269|PubMed:10683150, ECO:0000269|PubMed:12972549}. | Possible transcription factor. Specifically binds to theCT/GC-rich region of the interleukin-3 promoter and mediates taxtransactivation of IL-3. {ECO:0000269|PubMed:8035792}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for MRC2_VEZF1 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for MRC2_VEZF1 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| MRC2 | NDEL1, FBXO6, LGALS3, LGALS8, LGALS9, AKT1, BAG4, BRMS1, ESR2, PALB2, PAX2, PPM1D, PTPN1, RAF1, RB1CC1, XRCC3, FAM19A4, ST8SIA4, FAM19A3, LMAN2L, SCGB1D1, CER1, LYZL2, KNG1, TALDO1 | VEZF1 | ELAVL1, MEOX2, CTR9 |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for MRC2_VEZF1 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for MRC2_VEZF1 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | MRC2 | C0024667 | Animal Mammary Neoplasms | 1 | CTD_human |
| Hgene | MRC2 | C0024668 | Mammary Neoplasms, Experimental | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|